

**XTend Medical Corporation**  
**(XMDC)**  
**A Delaware Corporation**  
**May 10, 2012**

**Part A – General Company Information**

**Item 1: Exact name of the issuer and its predecessors:**

- XTend Medical Corporation since 9-07
- Formerly=Summus Works, Inc. until 9-07
- Formerly=Prime Rate Investors, Inc. until 2-06
- Note=10-12-04 State of Incorporation Nevada changed to Delaware
- Note=4-02 State of Incorporation Colorado changed to Nevada
- Formerly=Rocky Mountain Ginseng, Inc. until 6-02
- \*(Note:Mr. Friedman and Mr. Lisenby had not prior involvement with any company other than Summus Works, Inc.)

**Item 2: Company's Address**

XTend Medical Corporation  
10771 Sherman Way  
Sun Valley, CA 91352  
P: 818.255.2476  
F: 818.255.2122  
[www.xtendmedical.com](http://www.xtendmedical.com)

**Item 3:** THE JURISDICTIONS AND DATE OF THE ISSUER'S INCORPORATION OR ORGANIZATION

The Issuer, XTend Medical, was originally formed as Rocky Mountain Ginseng in 6-02 in Colorado. The company has since been changed and under the laws of the State of Delaware since 10-12-04.

**Part B: Share Structure**

**Item 4:** The company is currently authorized 1,750,000,000 shares with a par value of .000001 The company is also authorized 100,000,000 Preferred Shares with a par value of .000001

The company's current Cusip Number is 98417H 10 3

The company currently trades under the symbol: XMDC

SIC - Industry Classification

5047 - Medical and hospital equipment

**ITEM 5: PAR OR STATED VALUE AND DESCRIPTION OF THE SECURITY**

Common Shares par value: .000001

Preferred Shares: .000001

**ITEM 6: THE NUMBER OF SHARES AND TOTAL AMOUNT OF THE SECURITIES FOR EACH CLASS OF SECURITIES AUTHORIZED:**

Authorized Shares	1,750,000,000
Preferred Shares	100,000,000
Total Restricted Shares	922,031,385
Total Public Float	462,855,646
Total Outstanding	1,384,887,031

All Preferred Stock is convertible at a 10-1 ratio (Currently the company has only 3 shareholders with Preferred Stock that is convertible to 2.5 million Common Shares.

Item 7: The name and Address of the transfer agent:

Signature Stock Transfer, 2632 Coachlight Court

Plano, Texas 75093 Telephone 972.612.4120

The transfer agent is currently registered under the Exchange Act as listed on OTC Markets

**Part C: Business Information**

**ITEM 8: THE NATURE OF THE ISSUER'S BUSINESS**

XTend Medical is a C corporation under the laws of the State of Delaware. The company was originally formed in 2002 in the State of Colorado. It has been a Delaware corporation since February of 2006. The company was formerly Summus Works, Inc before the name was changed to XTend Medical in September of 2007. The company operates on a Fiscal Year ending in

December. The company will be filing for a name change in May of 2012 to change from XTend Medical Corporation to MultiCorp International, Inc.

The company recently came out of bankruptcy. The company was involved in litigation for two and half years based on the failure of another party to deliver assets the company had purchased in 2009 but never received. The subsequent legal proceedings have been completely settled and the company is no longer in bankruptcy or has any no other proceedings related to this matter.

The company is on target to acquire several entities over the next two years. These acquisitions should bring considerable revenue to the company as well as help the company to diversify into varying sectors of business that current management has profound experience in.

The company will continue to operate in the medical field as well as seek out opportunities that can assist the company in growing their revenues and subsequent profits in order to bring shareholder value. As with any business operating in today's environment, diversification will be a key component of the company in order to capitalize in today's business environment. The company will actively seek out and acquire companies that have superior products, seasoned management, and the ability to have true synergy with current management's vision.

#### **ITEM 9: THE NATURE AND EXTENT OF PRODUCTS OR SERVICES OFFERED**

The company currently sells medical products to varying physician groups and distributors. The company will continue to sell and provide medical products as well as acquire companies that have proper management, business plan, and potential to be able to add to the company's core principal of growth. The company doesn't foresee any limitations on their business from any governmental agencies presently.

However, the targeted acquisitions the company is currently doing their due diligence on have governmental restrictions associated with them. These restrictions will not hamper the company's business whatsoever and are line with the normal operating procedures of the potential acquisition.

#### **ITEM 10: THE NATURE AND EXTENT OF THE ISSUER'S FACILITIES**

The company currently leases 3000 sq' office and warehouse space in Sun Valley, CA.

#### **Part D: Management Structure and Financial Information**

#### **Item 11: THE NAMES OF THE CEO, PRESIDENT, AND MEMBERS OF THE BOARD OF DIRECTORS, AS WELL AS ANY CONTROL PERSONS.**

All of these officers and directors listed below can be reached at the company headquarters contact information listed above.

Paul D. Lisenby is the current Chairman and CEO of XTend Medical Corporation. Mr. Lisenby has been in his current position since July of 2007

Mr. Lisenby has a current salary of \$250,000 per year. Mr. Lisenby has deferred portions of his compensation package until a time wherein the company has sufficient capital to operate.

Mr. Lisenby holds approximately 519,755,350 shares of common stock of the company as of 09/22/11 report from the company's transfer agent. These shares were acquired through the company's change of ownership agreement between BioPharmetics, Inc and Summus Works, Inc in July of 2007.

---

Ben Friedman is the President of XTend Medical Corporation as well as a board member. Mr. Friedman has been president of the company since July of 2007.

Mr. Friedman has a current salary of \$250,000 per year. Mr. Friedman has deferred portions of his compensation package until a time wherein the company has sufficient capital to operate.

Mr. Friedman holds approximately 422,100,000 shares of common stock of the company as of 09/22/11 report from the company's transfer agent. These shares were acquired through the company's change of ownership agreement between BioPharmetics, Inc and Summus Works, Inc in July of 2007.

#### **11 B: Legal/Disciplinary History**

There are currently no legal proceedings against the CEO or President.

#### **11 C: Disclosure of Family Relationships**

None

#### **11 D: Disclosure of Related Party Transaction**

None

#### **11 E: Disclosure of Conflicts or Interests**

None

#### **Item 12: Financial Information**

The company's current financial information is posted on the OTC Markets website:

<http://www.otcm Markets.com/stock/XMDC/financials>

**Item 13:** <http://www.otcm Markets.com/stock/XMDC/financials>

**Item 14: Beneficial Owners**

Paul D. Lisenby 519,755,350 shares  
10771 Sherman Way  
Sun Valley, CA 91352

Ben Friedman 422,100,000  
10771 Sherman Way  
Sun Valley, CA 91352

**Item 15:** The name, address, telephone number, and email address of each of the following outside providers that advise the issuer on matters relating to operations, business development, and disclosure:

1. Investment Banker  
None
2. Promoters  
None
3. Counsel  
In progress of identifying
4. Public Relations Consultant  
None
5. Accountant  
Craig Ainge  
118 N 1600 W  
Mapleton, UT 84664  
[craigaingecpa@msn.com](mailto:craigaingecpa@msn.com)
6. Investor Relation  
Paul D. Lisenby – CEO  
XTend Medical Corporation  
10771 Sherman Way  
Sun Valley, CA 91352  
[paul@xtendmedical.com](mailto:paul@xtendmedical.com)
7. Other advisors  
None

## **Item 16: Management's Discussion**

### **Item 16 B: Management's Discussion and Analysis of Financial Condition and Results of Operations**

The company has been operating under very limited ability over the last two years due to the litigation the company was involved in. However, this hasn't stopped management from working continuously to bring in opportunities for the company. Management has identified and begun the due diligence process on two possible acquisitions for the company to gain revenues and profits and will look to close these acquisitions in at the end of the 2<sup>nd</sup> quarter of 2012.

The company will require operating capital to insure the business plan is followed. The company plans to raise capital through private investment, debt, convertible debentures, or other methods wherein the company raises funds under the best terms available.

The financial condition of the company is that it needs to raise capital to operate properly. Lacking proper funding, the company will be limited as to its growth. However, the current executives have experience in raising funds through many sources and will work diligently to insure the company has the proper capital needs in order to move the company in a positive direction.

## **Item 17: Issuance History**

List of Securities offering and Shares issued for services in the past two years.

On October 11, 2010, Mr. Paul D. Lisenby, CEO, exercised his option to convert his preferred shares into common shares. Mr. Lisenby converted 56,925,000 Preferred Shares into 569,250,000 Common Shares. This allowed the company to convert over the majority of the Preferred Shares that Mr. Lisenby held since July of 2007.

## **Item 18: Material Contracts**

At the present time the company has not entered into any contracts. However, once the due diligence process is completed on the two targeted acquisition, the company anticipates there will be several contracts that will need to be legally reviewed and subsequently signed.

### **Item 19: Articles of Incorporation and Bylaws**

See Filed PDF

### **Item 20: Purchase of Equity Securities by the Issuer and Affiliated Purchasers**


For the period ending December 31, 2011 the company has not sold or issued any new securities.

### **Item 21: Issuer's Certification**

I, Paul D. Lisenby, certify that:

1. I have reviewed the Information and Disclosure Statement of XTend Medical Corporation;
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement

Dated: May 10, 2012



---

Paul D. Lisenby

Chairman/CEO – XTend Medical Corporation

